MCID: BPL002
MIFTS: 50

Bipolar I Disorder

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Bipolar I Disorder

MalaCards integrated aliases for Bipolar I Disorder:

Name: Bipolar I Disorder 12 76 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:14042
ICD9CM 35 296.50
SNOMED-CT 68 49468007

Summaries for Bipolar I Disorder

Disease Ontology : 12 A bipolar disorder that is characterized by at least one manic or mixed episode.

MalaCards based summary : Bipolar I Disorder is related to bipolar disorder and depression. An important gene associated with Bipolar I Disorder is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are G-Beta Gamma Signaling and Neuroscience. The drugs Aripiprazole and Lithium carbonate have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and amygdala, and related phenotypes are behavior/neurological and muscle

Wikipedia : 76 Bipolar I disorder (BD-I; pronounced "type one bipolar disorder") is a bipolar spectrum disorder... more...

Related Diseases for Bipolar I Disorder

Diseases in the Bipolar Disorder family:

Bipolar Ll Disorder Bipolar I Disorder

Diseases related to Bipolar I Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 bipolar disorder 30.8 ANK3 BDNF COMT DAO DRD1 DTNBP1
2 depression 30.5 BDNF HTR1A HTR2A HTR2C SLC6A4
3 schizoaffective disorder 30.3 BDNF COMT DTNBP1 HTR2A SLC6A4
4 tardive dyskinesia 30.2 COMT HTR2A
5 anxiety 30.0 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
6 major depressive disorder 30.0 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
7 substance abuse 29.9 BDNF COMT SLC6A4
8 personality disorder 29.8 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
9 schizophrenia 29.7 BDNF COMT DAO DRD1 DTNBP1 HTR1A
10 attention deficit-hyperactivity disorder 29.5 BDNF COMT DRD1 HTR1A HTR2A HTR2C
11 borderline personality disorder 29.5 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
12 obsessive-compulsive disorder 29.4 BDNF COMT DRD1 HTR1A HTR2A HTR2C
13 autism 29.4 ANK3 BDNF COMT HTR1A HTR2A SLC6A4
14 mood disorder 29.4 BDNF COMT HTR1A HTR2A HTR2C PER3
15 mental depression 29.2 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
16 panic disorder 29.2 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
17 alcohol dependence 29.1 BDNF COMT DRD1 HTR1A HTR2A HTR2C
18 psychotic disorder 28.4 BDNF COMT DAO DRD1 DTNBP1 HTR1A
19 sexual disorder 10.2 HTR1A SLC6A4
20 schizophrenia 5 10.2 COMT HTR2A
21 atypical depressive disorder 10.2 HTR2A SLC6A4
22 schizophreniform disorder 10.2 COMT NRG1
23 alcoholic psychosis 10.2 HTR2A SLC6A4
24 postpartum depression 10.2 BDNF COMT SLC6A4
25 dysthymic disorder 10.2 HTR2A SLC6A4
26 schizoid personality disorder 10.2 HTR1A HTR2A
27 social phobia 10.2 HTR1A SLC6A4
28 hypoactive sexual desire disorder 10.2 HTR1A HTR2A
29 specific developmental disorder 10.2 BDNF COMT SLC6A4
30 substance-induced psychosis 10.1 HTR1A HTR2A
31 oppositional defiant disorder 10.1 COMT SLC6A4
32 kleptomania 10.1 HTR1A SLC6A4
33 early-onset schizophrenia 10.1 BDNF DRD1 HTR2A
34 cannabis dependence 10.1 COMT NRG1
35 fibromyalgia 10.1 COMT HTR2A SLC6A4
36 phobic disorder 10.1 COMT HTR1A SLC6A4
37 alexithymia 10.1 COMT HTR1A SLC6A4
38 brunner syndrome 10.1 COMT HTR1A SLC6A4
39 pathological gambling 10.1 DRD1 HTR2A SLC6A4
40 tobacco addiction 10.1 COMT HTR2A SLC6A4
41 drug-induced mental disorder 10.1 HTR1A HTR2A
42 drug psychosis 10.1 HTR1A HTR2A
43 central nervous system disease 10.1 BDNF HTR2A SLC6A4
44 traumatic brain injury 10.1 BDNF COMT
45 intermittent explosive disorder 10.1 HTR1A SLC6A4
46 serotonin syndrome 10.1 HTR1A HTR2A SLC6A4
47 agoraphobia 10.1 HTR1A SLC6A4
48 paranoid schizophrenia 10.1 BDNF COMT HTR2A SLC6A4
49 bulimia nervosa 10.0 BDNF COMT HTR2A SLC6A4
50 post-traumatic stress disorder 10.0 BDNF COMT HTR2A SLC6A4

Graphical network of the top 20 diseases related to Bipolar I Disorder:



Diseases related to Bipolar I Disorder

Symptoms & Phenotypes for Bipolar I Disorder

MGI Mouse Phenotypes related to Bipolar I Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 ANK3 BDNF COMT DAO DRD1 DTNBP1
2 muscle MP:0005369 9.43 DRD1 DTNBP1 EGR3 HTR2A HTR2C SLC6A4
3 nervous system MP:0003631 9.4 ANK3 BDNF COMT DAO DRD1 DTNBP1

Drugs & Therapeutics for Bipolar I Disorder

Drugs for Bipolar I Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
2
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 554-13-2
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
4
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
5
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 99-66-1 3121
6
Carbamazepine Approved, Investigational Phase 4,Phase 3,Phase 1 298-46-4 2554
7
Oxcarbazepine Approved Phase 4 28721-07-5 34312
8
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 1 132539-06-1 4585
9
Coal tar Approved Phase 4 8007-45-2
10
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
11
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84057-84-1 3878
12 tannic acid Approved Phase 4,Not Applicable
13
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
14
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
15
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
16
Infliximab Approved Phase 4 170277-31-3
17
Choline Approved, Nutraceutical Phase 4 62-49-7 305
18 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Not Applicable 111974-72-2
19 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
21 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antimanic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1
28 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Autonomic Agents Phase 4,Phase 3,Phase 1
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 1
31 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
32 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
34 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
35 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2,Phase 1
36 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Sodium Channel Blockers Phase 4,Phase 3,Phase 2,Phase 1
38 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Antiemetics Phase 4,Phase 3,Phase 1
42 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 1
43 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
46 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
47 Appetite Depressants Phase 4
48 Anti-Obesity Agents Phase 4,Phase 3
49 Vasoconstrictor Agents Phase 4
50 Cytidine Diphosphate Choline Phase 4

Interventional clinical trials:

(show top 50) (show all 218)
# Name Status NCT ID Phase Drugs
1 Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients Unknown status NCT01710163 Phase 4 Lithium;Aripiprazole
2 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
3 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
4 Efficacy and Safety of Utapine vs. Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
5 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder Completed NCT00034580 Phase 4 olanzapine;risperidone
6 A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode Completed NCT00277212 Phase 4 Lamotrigine + Aripiprazole;Lamotrigine + Placebo
7 A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients Completed NCT00402324 Phase 4 olanzapine;placebo;divalproex
8 The Young Adult and Pediatric Bipolar Study Completed NCT00350857 Phase 4 Extended-Release Carbamazepine
9 The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Completed NCT00044187 Phase 4 Sibutramine
10 Study in Adolescents With Schizophrenia or Bipolar Disorder Completed NCT00982020 Phase 4 Olanzapine
11 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
12 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
13 Olanzapine vs. Comparator and Placebo in the Treatment of Patients With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
14 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4 Citicoline;Placebo
15 Efficacy of Combined Treatment for Young Bipolar I Disorder Completed NCT00976794 Phase 4 lithium plus carbamazepine;lithium plus valproate
16 Olanzapine Plus Carbamazepine in the Treatment of Bipolar I Mania Completed NCT00190892 Phase 4 olanzapine;carbamazepine
17 Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
18 A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania Completed NCT00261443 Phase 4 Lithium or Valproate with placebo (PBO);Lithium or Valproate with Aripiprazole
19 A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression Completed NCT00844857 Phase 4 Olanzapine Fluoxetine Combination (OFC);Placebo
20 Sequential Multiple Assignment Treatment for Bipolar Disorder Completed NCT01588457 Phase 4 Lithium/Lithium Carbonate;Divalproex;Lamotrigine;Quetiapine
21 ABLE: Abilify in Bipolar Disorder for Long-term Effectiveness Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo
22 Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder Completed NCT00672490 Phase 4 Quetiapine Fumarate;Lithium
23 A Study of Infliximab for Treatment Resistant Major Depression Completed NCT00463580 Phase 4 Infliximab;Placebo
24 DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder Recruiting NCT02623504 Phase 4 Carbamazepine;Placebo
25 A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder Terminated NCT03643159 Phase 4 aripiprazole or other oral antipsychotics
26 Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients Terminated NCT00139074 Phase 4 Quetiapine fumarate;sodium valproate
27 Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotic Mania Withdrawn NCT01495156 Phase 4 Lithium treatment in combination with a SGA (Second Generation Antipsychotic);Placebo/Adjunctive SGA treatment
28 Safety and Efficacy Study of Lithium in Bipolar Disorder Unknown status NCT00422331 Phase 3 Lithium Carbonate Capsule
29 Lithium Versus Divalproex for Treating Pediatric Bipolar Disorder Unknown status NCT00221429 Phase 3 lithium sodium divalproex
30 Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder Completed NCT01059539 Phase 3 cariprazine
31 A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents Completed NCT00195780 Phase 3 Divalproex Sodium (Depakote ER)
32 Safety and Efficacy of Cariprazine for Bipolar I Disorder Completed NCT01058668 Phase 3 Cariprazine;Placebo
33 A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. Completed NCT01986114 Phase 3 SM-13496 (lurasidone HCl)
34 A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Disorder Completed NCT00490971 Phase 3 Olanzapine;Paliperidone ER;Placebo
35 Efficacy & Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder Completed NCT00107731 Phase 3 quetiapine fumarate;lithium;divalproex
36 Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder Completed NCT00227305 Phase 3 quetiapine fumarate
37 This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 Completed NCT01575561 Phase 3 Lurasidone
38 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00238485 Phase 3 Licarbazepine
39 Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed Completed NCT00618748 Phase 3 Olanzapine
40 A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder Completed NCT03259555 Phase 3 Brexpiprazole;Placebo
41 Lurasidone and Cognition in Bipolar I Disorder Completed NCT02147379 Phase 3 Lurasidone
42 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01305408 Phase 3 Armodafinil;Placebo
43 Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072630 Phase 3 Armodafinil;Placebo
44 A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder Completed NCT01072929 Phase 3 Armodafinil;Placebo
45 Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Completed NCT00129220 Phase 3 olanzapine;haloperidol;placebo
46 Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed) Completed NCT00265330 Phase 3 Ziprasidone oral capsules
47 Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients Completed NCT01567527 Phase 3 Intramuscular (IM) Depot Aripiprazole;Intramuscular (IM) Depot Placebo
48 An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. Completed NCT00228059 Phase 3 Licarbazepine
49 Aripiprazole in Children and Adolescents With Bipolar I Disorder Completed NCT00110461 Phase 3 Aripiprazole;Aripiprazole;placebo
50 A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode Completed NCT00094432 Phase 3 Aripiprazole;Placebo

Search NIH Clinical Center for Bipolar I Disorder

Genetic Tests for Bipolar I Disorder

Anatomical Context for Bipolar I Disorder

MalaCards organs/tissues related to Bipolar I Disorder:

41
Brain, Cortex, Amygdala, Testes, Bone, Cingulate Cortex, Eye

Publications for Bipolar I Disorder

Articles related to Bipolar I Disorder:

(show top 50) (show all 784)
# Title Authors Year
1
The association between mood state and chronobiological characteristics in bipolar I disorder: a naturalistic, variable cluster analysis-based study. ( 29457195 )
2018
2
Can Residual Symptoms During Inter-Episode Period after Partial Remission in Bipolar I Disorder Have Cyclic Patterns with Specific Frequencies? ( 29486550 )
2018
3
Lack of emotional gaze preferences using eye-tracking in remitted bipolar I disorder. ( 29968068 )
2018
4
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA. ( 29694243 )
2018
5
Quetiapine Related Acute Paralytic Ileus in a Bipolar I Disorder Patient with Successful Low Dose Amisulpride Substitution: A Case Report. ( 29739140 )
2018
6
The effects of psychoeducational family intervention on coping strategies of relatives of patients with bipolar I disorder: results from a controlled, real-world, multicentric study. ( 29692615 )
2018
7
Cognitive functioning in first episode bipolar I disorder patients with and without history of psychosis. ( 29055258 )
2018
8
Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study. ( 29789269 )
2018
9
Psychosocial functioning in patients with psychotic and non-psychotic bipolar I disorder. A comparative study with individuals with schizophrenia. ( 29316520 )
2018
10
Cardiometabolic risks and omega-3 index in recent-onset bipolar I disorder. ( 29479787 )
2018
11
Influence of age at onset on the course and outcome of bipolar I disorder: Findings from a retrospective study. ( 29494947 )
2018
12
Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients. ( 29391801 )
2018
13
An overview of pharmacotherapy for bipolar I disorder. ( 29361880 )
2018
14
The association between social skills deficits and family history of mood disorder in bipolar I disorder. ( 29590265 )
2018
15
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400A mg in bipolar I disorder in the USA. ( 29694244 )
2018
16
Could schizoaffective disorder, schizophrenia and bipolar I disorder be distinguishable using cognitive profiles? ( 29852325 )
2018
17
No neuronal autoantibodies detected in plasma of patients with a bipolar I disorder. ( 29136601 )
2018
18
Perception of inpatients following remission of a manic episode in bipolar I disorder on a group-based Psychoeducation program: a qualitative study. ( 29378562 )
2018
19
Predictors and outcomes of somatization in bipolar I disorder: A latent class mixture modeling approach. ( 29174742 )
2018
20
Comparison of salivary testosterone levels in different phases of bipolar I disorder and control group. ( 29887899 )
2018
21
Mixed Features in Bipolar I Disorder and the Effect of Lithium on Suicide. ( 29301424 )
2018
22
Psychoeducation for psychiatric inpatients following remission of a manic episode in bipolar I disorder: A randomized controlled trial. ( 29578271 )
2018
23
Association of intracortical myelin and cognitive function in bipolar I disorder. ( 29536533 )
2018
24
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. ( 29174738 )
2018
25
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. ( 29886522 )
2018
26
Secular trends in the age at onset of bipolar I disorder - Support for birth cohort effects from interational, multi-centre clinical observational studies. ( 29734127 )
2018
27
Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. ( 29909303 )
2018
28
The economic burden of bipolar I disorder in the United States in 2015. ( 28961441 )
2018
29
Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder. ( 29017067 )
2018
30
Assessment of cognitive functions in bipolar I disorder: A 1-year naturalistic follow-up study. ( 29314557 )
2018
31
Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults. ( 29341822 )
2018
32
Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder. ( 29433844 )
2018
33
Transitioning from Bipolar II to Bipolar I Disorder in Late Life: Implications for Practice. ( 29725185 )
2018
34
Double trouble: weekend sleep changes are associated with increased impulsivity among adolescents with bipolar I disorder. ( 29781205 )
2018
35
Regional cortical thinning in young adults with schizophrenia but not psychotic or non-psychotic bipolar I disorder. ( 29992455 )
2018
36
Comparison of Efficiency GEE and QIF Methods for Predicting Factors Affecting on Bipolar I Disorder Under Complete-case in a Longitudinal Studies. ( 30061782 )
2018
37
Therapeutic effects of mobile-based text message reminders for medication adherence in bipolar I disorder: Are they maintained after intervention cessation? ( 30081390 )
2018
38
Aggression among 216 patients with a first-psychotic episode of bipolar I disorder. ( 30097737 )
2018
39
Post hoc analyses of asenapine treatment in pediatric patients with bipolar I disorder: efficacy related to mixed or manic episode, stage of illness, and body weight. ( 30122926 )
2018
40
Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder. ( 30129771 )
2018
41
Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A 1H-MRS study. ( 30130684 )
2018
42
Problematic definitions of bipolar I disorder and mixed episode in the upcoming ICD-11. ( 30144038 )
2018
43
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study. ( 30145513 )
2018
44
Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data. ( 30206822 )
2018
45
Relationship Between Cognitive Function and Clinical Features in Patients With Bipolar I Disorder. ( 30286842 )
2018
46
Differences in Psychopathology between Offspring of Parents with Bipolar I Disorder and Those with Bipolar II Disorder: A Cross-Sectional Study. ( 30360028 )
2018
47
Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder. ( 30376745 )
2018
48
Late-onset Bipolar I Disorder. ( 30410848 )
2018
49
Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder. ( 30447566 )
2018
50
Differences between unipolar mania and bipolar-I disorder: Evidence from nine epidemiological studies. ( 30475430 )
2018

Variations for Bipolar I Disorder

Expression for Bipolar I Disorder

Search GEO for disease gene expression data for Bipolar I Disorder.

Pathways for Bipolar I Disorder

Pathways related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 BDNF DRD1 HTR2A HTR2C TUBA8
2 12.24 COMT DTNBP1 EGR3 HTR1A
4
Show member pathways
11.94 DRD1 HTR2A HTR2C
5 11.83 BDNF HTR1A HTR2A SLC6A4
6
Show member pathways
11.62 DRD1 HTR1A HTR2A HTR2C
7 11.52 HTR1A HTR2A HTR2C SLC6A4
8 11.2 DRD1 HTR2A HTR2C TUBA8
9
Show member pathways
10.89 COMT SLC6A4
10 10.76 HTR2A HTR2C
11 10.37 HTR1A HTR2A HTR2C SLC6A4

GO Terms for Bipolar I Disorder

Cellular components related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.88 DRD1 HTR1A HTR2A HTR2C NRG1 SLC6A4
2 postsynaptic membrane GO:0045211 9.67 ANK3 COMT DTNBP1 GRID1
3 glutamatergic synapse GO:0098978 9.55 DRD1 DTNBP1 GRID1 HTR2A NRG1
4 integral component of presynaptic membrane GO:0099056 9.5 DRD1 HTR2A SLC6A4
5 integral component of postsynaptic membrane GO:0099055 9.43 DRD1 HTR2A SLC6A4
6 dendrite GO:0030425 9.43 ANK3 BDNF COMT HTR1A HTR2A HTR2C
7 axon GO:0030424 9.1 ANK3 BDNF COMT DTNBP1 HTR2A NRG1
8 plasma membrane GO:0005886 10.13 ANK3 COMT DRD1 DTNBP1 GRID1 HTR1A

Biological processes related to Bipolar I Disorder according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 ANK3 DRD1 DTNBP1 NRG1 SLC6A4
2 response to drug GO:0042493 9.8 COMT DRD1 HTR2A HTR2C SLC6A4
3 locomotory behavior GO:0007626 9.72 DRD1 HTR2C NRG1
4 circadian rhythm GO:0007623 9.71 EGR3 PER3 SLC6A4
5 synapse assembly GO:0007416 9.69 BDNF DRD1 NRG1
6 regulation of synaptic vesicle exocytosis GO:2000300 9.67 DRD1 DTNBP1 HTR2A
7 feeding behavior GO:0007631 9.62 DRD1 HTR2C
8 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.62 HTR1A HTR2A
9 regulation of dopamine secretion GO:0014059 9.61 DTNBP1 HTR2A
10 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.61 DRD1 HTR2C
11 behavioral fear response GO:0001662 9.61 DRD1 HTR1A HTR2C
12 activation of phospholipase C activity GO:0007202 9.6 BDNF HTR2A
13 neuronal action potential GO:0019228 9.59 ANK3 DRD1
14 temperature homeostasis GO:0001659 9.58 DRD1 HTR2A
15 behavioral response to cocaine GO:0048148 9.58 DRD1 HTR2A
16 vasoconstriction GO:0042310 9.57 HTR1A SLC6A4
17 dopamine metabolic process GO:0042417 9.56 COMT DRD1
18 memory GO:0007613 9.56 BDNF DRD1 HTR2A SLC6A4
19 regulation of dopamine metabolic process GO:0042053 9.52 DRD1 HTR1A
20 peripheral nervous system development GO:0007422 9.5 BDNF EGR3 NRG1
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.46 HTR2A HTR2C
22 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.46 DRD1 HTR1A HTR2A HTR2C
23 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.37 HTR2A HTR2C
24 behavior GO:0007610 9.13 HTR1A HTR2A HTR2C
25 serotonin receptor signaling pathway GO:0007210 8.8 HTR1A HTR2A HTR2C

Molecular functions related to Bipolar I Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.43 HTR1A HTR2A HTR2C
2 G protein-coupled serotonin receptor activity GO:0004993 9.33 HTR1A HTR2A HTR2C
3 G-protein alpha-subunit binding GO:0001965 9.32 DRD1 HTR2A
4 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.96 HTR2A HTR2C
5 serotonin binding GO:0051378 8.92 HTR1A HTR2A HTR2C SLC6A4

Sources for Bipolar I Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....